Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II cli (Q33418923)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II cli	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II cli (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Haruyuki Takaki

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Koichiro Yamakado

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Masakatsu Tsurusaki

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Taku Yasumoto

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yasutaka Baba

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yoshiaki Narimatsu

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Masashi Shimohira

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Masato Yamaguchi

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kunihiro Matsuo

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yoshitaka Inaba

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Koji Mikami

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ryohei Watanabe

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Norifumi Nishida

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hiroshi Anai

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hideaki Kakizawa

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shozo Hirota

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

29 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

International Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

745-754

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Epidemiology of viral hepatitis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Focus on hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call(®)) in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Hepatic Arterial Infusion Therapy with a Fine Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Transcatheter oily chemoembolization of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0773-4

21 January 2018

Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment strategies for hepatocellular carcinoma in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Chemotherapy combined with Lipiodol. In vitro study of the kinetics of release of adriamycin]

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of intrahepatic arterial infusion of 4'-epidoxorubicin with Lipiodol versus 4'-epidoxorubicin alone in the treatment of hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical utility of transarterial infusion chemotherapy using cisplatin-lipiodol emulsion for unresectable hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benign and malignant portal vein thrombosis: differentiation by CT characteristics

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10147-014-0773-4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

release_57y3hnklcjfypcgbqct7zxau3u

1 reference

https://api.fatcat.wiki/v0/release/57y3hnklcjfypcgbqct7zxau3u

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33418923&oldid=2195343780"